Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency is a rare genetic condition that weakens the immune response to certain germs. People with this condition often get repeated or severe infections from mycobacteria, including BCG vaccine strains and environmental mycobacteria, and sometimes serious salmonella infections. It usually starts in infancy or childhood and tends to be lifelong. Treatment often includes prompt antibiotics, antifungals if needed, and immune therapies such as interferon‑gamma; some may benefit from stem cell transplant in select cases. The outlook varies with infection severity and access to care, but many people with Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency do well with early diagnosis and ongoing specialist care.
Overview
Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiencySymptoms
Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency often shows early signs in infancy or childhood, sometimes after BCG vaccination. Features include severe or recurrent mycobacterial or Salmonella infections with fever, swollen lymph nodes, cough, or widespread illness.
Outlook and prognosis
Most people with Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency face repeated, sometimes severe infections, especially from BCG, environmental mycobacteria, and salmonella. With early diagnosis, preventive antibiotics, prompt treatment, and interferon‑gamma, many achieve good long‑term control. Outcomes vary; specialist follow‑up is essential.
Causes and risk factors
Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency results from harmful variants in both IL12B copies, typically inherited from carrier parents (autosomal recessive). Risk rises with family history, parental relatedness, and mycobacterial exposure; malnutrition can worsen infections.
Genetic influences
Genetics are central in Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency. It’s caused by inherited changes in the IL12B gene, usually autosomal recessive, leading to absent IL-12/IL-23 signaling. Family testing and genetic counseling are important.
Diagnosis
Doctors suspect it from clinical features: recurrent or severe mycobacterial infections and weak interferon‑gamma responses on blood tests. Genetic tests confirming two IL12B gene changes establish the genetic diagnosis of Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency.
Treatment and drugs
Treatment focuses on rapidly treating infections and strengthening the immune response. People with Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency often receive prolonged, targeted antibiotics for mycobacteria and interferon‑gamma injections to boost defense. Vaccination with BCG is generally avoided.
Symptoms
Repeated infections that are tough to shake are a common early clue. Early on, this might look like fevers that keep returning, swollen glands during illnesses, or a vaccine site that doesn’t heal as expected. Early features of Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency often include problems after the BCG vaccine, illness from environmental mycobacteria, and bouts of Salmonella. Some people also deal with yeast infections of the mouth, skin, or nails.
After the BCG vaccine (used in many countries), the shot area may stay open or drain for weeks. Nearby lymph nodes can enlarge and become tender. This can happen in Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency.
Painless or tender lumps in the neck, armpit, or groin can develop during infections. They may slowly enlarge or form draining tracts.
Fevers come back repeatedly with infections and may last longer than expected. Standard treatment may help briefly, but the infection can return.
Infections from BCG or environmental mycobacteria can involve skin, lungs, or bones, causing draining sores, cough, or bone pain. In Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency, these infections are often more severe or long‑lasting.
How people usually first notice Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency?
Many families first notice something is unusual when a baby or young child develops severe or repeated infections after routine Bacillus Calmette–Guérin (BCG) vaccination or exposure to environmental nontuberculous mycobacteria, infections that are typically mild in others. Doctors may see poor response to standard treatments, unusual complications like persistent lymph node swelling, or serious infections with certain bacteria and fungi that need the immune messenger IL-12 to fight them. If this pattern appears, especially with a family history or in communities where BCG is given at birth, clinicians consider the first signs of Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency and confirm it with immune function tests and genetic testing.
Types of Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency
People with Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency are born with a specific immune signaling problem that makes it hard to fight certain bacteria and some other germs. In everyday life, this often shows up as serious or stubborn infections after routine exposures, such as the BCG vaccine given at birth in many countries or from environmental mycobacteria found in soil and water. Clinicians often describe them in these categories: variants of IL-12/IFN-γ pathway defects that differ by the exact gene involved, and IL12B deficiency is one well-defined subtype. Not everyone will experience every type of infection, but understanding the main variants of Mendelian susceptibility to mycobacterial diseases can help explain why symptoms and severity vary and clarify the types of MMDS seen across families.
IL12B deficiency
This variant involves a complete lack of the IL-12 p40 subunit, which blocks IL-12 and IL-23 signaling to activate interferon-gamma. People often develop severe or recurrent infections with BCG after vaccination, environmental nontuberculous mycobacteria, and sometimes Salmonella.
IL12RB1 deficiency
This closely related variant affects the IL-12 receptor beta-1, disrupting responses to IL-12 and IL-23 similarly to IL12B deficiency. Symptoms can mirror IL12B deficiency with mycobacterial and Salmonella infections, though exact severity and age at first infection may differ between families.
IFNGR1/IFNGR2 defects
These variants impair the interferon-gamma receptor, reducing the body’s ability to respond to interferon-gamma signals. People may have earlier, more severe or persistent mycobacterial infections, and some forms lead to very severe disease in infancy.
STAT1 deficiency
Variants affecting STAT1 can blunt signaling downstream of interferon-gamma and interleukins. Depending on whether the defect is partial or complete, infections with mycobacteria may range from recurrent but manageable to severe and disseminated.
IRF8 deficiency
This rare variant alters development and function of certain immune cells that help control intracellular bacteria. People can present in infancy or childhood with severe mycobacterial infections and sometimes additional bacterial infections.
TYK2 deficiency
This variant affects a signaling protein needed for multiple cytokine pathways, including interleukin and interferon routes. People may have mycobacterial and viral infections and variable severity, depending on the specific change in the gene.
Other pathway genes
Less common variants in genes like NEMO (IKBKG), CYBB, or STAT3 can also produce a Mendelian susceptibility to mycobacterial diseases phenotype. Symptoms depend on the exact gene and may include broader immune problems beyond mycobacteria, with differing risks for bacterial or fungal infections.
What genetics can tell you about symptoms
People with complete IL12B deficiency often get severe, recurrent infections from weak mycobacteria (like BCG vaccine or environmental mycobacteria) and Salmonella. The IL12B gene change blocks IL-12/IL-23 signals, weakening interferon-gamma responses that normally help immune cells kill these germs.
Causes and risk factors
This condition is caused by inheriting two nonworking copies of the IL12B gene. It is inherited in an autosomal recessive pattern and weakens defenses against mycobacteria. Genes set the stage, but environment and lifestyle often decide how the story unfolds. Risk factors for Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency include exposure to BCG vaccine, tuberculosis, or environmental mycobacteria. Family history, parental relatedness, crowded settings, and poor nutrition can raise infection risk.
Environmental and biological risk factors
Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency is present from birth, but the chance of getting sick depends strongly on exposures and other body factors. Some risks are carried inside the body, others come from the world around us. For some families, early symptoms of Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency appear after a newborn BCG vaccine or later with everyday contact with water or soil. Below are environmental and biological elements that can raise risk.
This live vaccine can trigger serious mycobacterial infection in people with Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency. Risk is highest when given in the newborn period.
Living with or spending many hours near someone with active tuberculosis increases exposure to mycobacteria. People with the condition are more likely to become ill after such close contact.
Residence or travel in areas where tuberculosis is common increases the number of exposures. For those with IL12B deficiency, repeated exposures raise the chance of infection.
Environmental mycobacteria live in household plumbing, shower aerosols, and natural soils. Frequent contact can raise risk in Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency.
Genetic risk factors
Genetic causes of Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency center on changes in the IL12B gene that knock out a key immune signal. This form is passed down in an autosomal recessive way, so both gene copies must be altered for the condition to appear. Some risk factors are inherited through our genes. Knowing who carries these changes helps explain why infections can be unusually severe early in life and guides testing for relatives.
IL12B gene variants: Changes in both copies of the IL12B gene stop the body from making the shared p40 piece of IL-12 and IL-23. Without this piece, key immune signals are disrupted. This sets the stage for Mendelian susceptibility to mycobacterial diseases.
Autosomal recessive pattern: A child must inherit one nonworking IL12B gene from each parent to be affected. Parents who each carry a single change are usually healthy carriers. Each pregnancy then has a 25% (1 in 4) chance for an affected child.
IFN-gamma pathway: Loss of IL-12/IL-23 signaling lowers interferon-gamma responses that normally control mycobacteria. This immune pathway change explains the specific infection risk. It does not affect all parts of immunity equally.
Family history clues: Relatives with severe illness after BCG vaccination or unusual mycobacterial or Salmonella infections can point to this inherited risk. Siblings of someone with confirmed IL12B deficiency have a higher chance of being affected or carriers. Genetic counseling can help map risks for future pregnancies.
Complete deficiency factor: This condition involves complete loss of IL12B function, not a partial drop. Confirming the exact gene change helps distinguish it from other genetic causes of mycobacterial susceptibility. Severity can vary even within the same family.
Lifestyle risk factors
Lifestyle habits do not cause this condition, which is an inherited immune pathway defect. However, daily choices can influence exposure to mycobacteria and Salmonella, how severe infections become, and how well treatments work. This overview focuses on how lifestyle affects Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency and highlights lifestyle risk factors for Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency.
Undercooked poultry/eggs and unpasteurized dairy raise exposure to Salmonella, which is a known threat in IL12B deficiency. Strict food handling, thorough cooking, and avoiding high‑risk foods can reduce invasive Salmonella infections.
Nontuberculous mycobacteria thrive in hot tubs, humidifiers, and potting soil. Limiting exposure, using well-maintained equipment, and wearing gloves/masks for dusty gardening can lower infection risk.
Time spent in TB-endemic settings, crowded clinics, or poorly ventilated spaces increases mycobacterial exposure. Planning travel, masking in high-risk environments, and prioritizing ventilation can reduce exposure.
Active and secondhand smoke impair lung macrophages and mucociliary clearance, weakening defense against mycobacteria. Avoiding smoke improves airway defenses and may lessen respiratory complications during infections.
Risk prevention
Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency is genetic, so you can’t prevent the condition itself, but you can lower the chance of serious infections. Prevention can mean both medical steps, like targeted medicines, and lifestyle steps, like food and water safety. Work with an immunology team to plan vaccines, travel, and what to do if symptoms appear. Early attention to infections often keeps small problems from becoming major ones.
See an immunology/infectious-disease team regularly to map out prevention and treatment steps. They may recommend interferon-gamma or preventive antibiotics in specific situations.
Skip the BCG tuberculosis vaccine, which can trigger severe infection in this condition. If it was given already, your care team may monitor closely or use preventive treatment.
Keep up with inactivated vaccines (like flu shots and routine childhood vaccines) to cut everyday infection risk. Ask your team which live vaccines are safe or should be avoided with IL12B deficiency.
Screen close contacts for tuberculosis and treat any exposure quickly. In higher-risk settings, limit close contact with people who have a chronic cough and ensure good ventilation.
Transmission
Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency is a genetic immune condition, not contagious, and it cannot be “caught” or spread through contact. It is usually inherited in an autosomal recessive pattern: a child is affected when they receive two nonworking copies of the IL12B gene, one from each parent, who are typically healthy carriers. When both parents are carriers, each pregnancy has a 25% (1 in 4) chance of a child with Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency, a 50% (1 in 2) chance the child will be a carrier, and a 25% chance of inheriting two working copies. Carrier testing and family genetic counseling can help clarify how Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency is inherited and future risks. People living with this condition can pass a single nonworking gene copy to their children, but a child would only develop the condition if the other parent also passes on a nonworking copy.
When to test your genes
This is a rare, inherited immune condition, so gene testing is appropriate when there’s a history of severe or unusual mycobacterial infections (like BCG complications or atypical mycobacteria), especially in childhood, or when close relatives are affected. Test before live mycobacterial vaccines. Results guide tailored antibiotics, immune therapy, and family counseling.
Diagnosis
When testing is considered, doctors look for a pattern of hard‑to‑treat mycobacterial infections, especially after BCG vaccination or from environmental mycobacteria, sometimes alongside repeat Salmonella infections. Many people feel relief just knowing what’s really going on. For Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency, confirmation typically blends infection evidence with targeted immune function tests and genetic analysis. Early symptoms of this condition can be subtle, so the diagnosis often pulls together details from different parts of your medical history and lab results.
Recurrent or severe infections with BCG or environmental mycobacteria raise early suspicion, sometimes with repeat Salmonella infections. Doctors also consider age at first infection, severity, and response to standard antibiotics. A careful exam looks for swollen lymph nodes, bone pain, or lung issues that hint at infection sites.
Cultures and PCR help identify the exact mycobacterial species and guide antibiotic choices. Finding BCG or non‑tuberculous mycobacteria in tissue or fluid supports the pattern seen in this condition. Drug‑susceptibility testing helps tailor treatment while evaluation continues.
Basic labs such as a complete blood count and immunoglobulin levels check for common immune problems. HIV testing and other labs may help rule out common conditions. Normal results here can point attention to more specific pathways like IL‑12 and interferon‑gamma.
Specialized blood tests assess the IL‑12/interferon‑gamma pathway. Cells are stimulated in the lab to see whether IL‑12 is produced and whether interferon‑gamma release is appropriately triggered. In complete il12b deficiency, IL‑12 production is typically very low or absent, with reduced downstream interferon‑gamma responses.
Stages of Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency
Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency does not have defined progression stages. It is a lifelong genetic difference in the immune system, and problems tend to show up as infections that come and go rather than a steady, step-by-step decline. Early symptoms of Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency may include severe or unusual mycobacterial infections after BCG vaccination or environmental exposure, and sometimes repeated Salmonella infections. Doctors confirm the diagnosis by reviewing your infection history, running immune function blood tests, and confirming changes in the IL12B gene; genetic testing may be offered to clarify certain risks.
Outlook and prognosis
Looking ahead can feel daunting, but many people with Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency do well when infections are recognized early and treated promptly. In everyday life, this condition tends to show up as repeated or unusually severe infections from BCG vaccine, nontuberculous mycobacteria, or salmonella; early symptoms of IL12B deficiency can include stubborn fevers, swollen lymph nodes after infant vaccination, or recurrent gut infections. Severe infections can be life-threatening without quick care, but with targeted antibiotics, antifungals when needed, and immune-boosting treatments like interferon-gamma, the immediate risk often falls. When infections are controlled and preventive strategies are in place, many living with IL12B deficiency attend school or work and lead active lives between flares.
Prognosis refers to how a condition tends to change or stabilize over time. For IL12B deficiency, the long‑term outlook largely depends on how fast infections are diagnosed, access to specialized care, and how well preventive measures are followed. Children typically face the highest risk period, especially around vaccination and early exposures; over time, most people see fewer severe infections as triggers are managed and care plans mature. Mortality is possible in severe, untreated cases—especially with disseminated mycobacterial disease—but published case series suggest survival improves markedly with modern antibiotics, interferon‑gamma, and careful follow‑up.
With ongoing care, many people maintain good overall health between infections and avoid long hospital stays. Regular monitoring to catch new symptoms early, prompt cultures to guide antibiotics, and vaccination planning with an immunology team can reduce complications. Talk with your doctor about what your personal outlook might look like, including plans for travel, food safety to reduce salmonella risk, and what to do if fevers or swollen nodes appear. Genetic testing can sometimes provide more insight into prognosis and help tailor family counseling and preventive strategies.
Long-term effects
Living day to day, people with Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency often face infections that come back or last longer than usual, which can affect school, work, and family plans. Long-term effects vary widely, and they depend on which germs were involved and how early care started. Families sometimes recall early symptoms of Mendelian susceptibility to mycobacterial diseases showing up in childhood, especially after exposure to Bacille Calmette–Guérin (BCG) vaccine or environmental mycobacteria. Over time, the outlook is often good with the right care plan, yet some may have lasting changes in the lungs, bones, or lymph nodes after severe infections.
Infections with BCG or environmental mycobacteria can come back over the years. They may stay in one area or spread, leading to repeated courses of treatment. This pattern can leave behind scarring in affected tissues.
Disseminated infection can cause long hospital stays and complications. The highest risk is often in childhood, but adults can be affected too. Outcomes improve when infections are found and treated promptly.
Invasive Salmonella infections can recur and may be serious. People with this condition may experience bloodstream or deep tissue infections. Relapses can occur even after an initial recovery.
Repeated chest infections can lead to airway widening (bronchiectasis) and reduced exercise tolerance. Chronic cough and more frequent respiratory infections may follow. Some people with Mendelian susceptibility to mycobacterial diseases have lasting changes on chest imaging.
How is it to live with Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency?
Living with Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency often means staying alert to infections that most people’s immune systems easily control, especially after certain live vaccines or exposures to environmental mycobacteria. Daily life can include regular check-ins with infectious disease and immunology teams, rapid evaluation of fevers or unusual lymph node swelling, careful vaccine planning (avoiding live mycobacterial vaccines), and sometimes long courses of antibiotics if infections occur. Many find that family routines adapt—planning travel and activities with infection risk in mind—and close contacts learn to spot early signs of illness and support prompt care. With a clear plan, good hygiene, and specialist guidance, people can attend school, work, and family events while balancing prevention and quick treatment when needed.
Treatment and drugs
Treatment for Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency focuses on preventing and controlling infections, especially from weak mycobacteria like BCG vaccine strains and nontuberculous mycobacteria. Doctors commonly use prolonged, combination antibiotics tailored to the specific mycobacterial species, sometimes for many months, and add medicines that replace the missing immune signal, such as interferon-gamma injections, to boost the body’s ability to fight these germs. If infections are severe or keep coming back, care teams may use additional antibiotics, adjust doses, and closely monitor for side effects with regular blood tests and imaging. Supportive care can make a real difference in how you feel day to day, including vaccines that are safe for people with this condition (not live vaccines), nutrition support, and prompt treatment of any new fevers, cough, weight loss, or swollen lymph nodes. In rare, difficult cases, bone marrow transplant may be considered at specialized centers, and your doctor can help weigh the pros and cons of each option.
Non-drug treatment
Daily life with Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency often centers on preventing germs that can cause serious infections and spotting problems early. Alongside medicines, non-drug therapies can lower infection risk and support everyday routines. Plans are tailored to age, travel, and local exposures, and they usually involve the whole household. Knowing the early symptoms of Mendelian susceptibility to mycobacterial diseases—like stubborn fevers or swollen glands that don’t settle—helps people seek care promptly.
Wash hands with soap and water before eating and after using the bathroom or touching animals. Carry alcohol-based sanitizer for times when sinks aren’t available. Make it a habit for everyone in the home.
Avoid undercooked meat, raw eggs, unpasteurized milk, and soft cheeses made from raw milk to lower salmonella risk. Rinse produce well and keep raw and cooked foods separate. When in doubt, heat thoroughly to steaming hot.
Drink treated, filtered, or boiled water, especially when traveling or if local water quality is uncertain. Avoid swallowing water in pools, lakes, and hot tubs. Use clean water for brushing teeth and making ice.
Limit contact with soil, dust, and aerosols that can carry nontuberculous mycobacteria, such as during gardening or power-washing. Wear gloves and a well-fitted mask for messy outdoor tasks. Shower after activities that kick up dust.
Your genes may have an impact on how drugs work for you
Genes can change how well certain antibiotics, antifungals, and interferon‑gamma work, and can affect side‑effect risk. In complete IL12B deficiency, treatment choices and dosing often hinge on genetic testing to guide safer, more effective therapy.
Pharmacological treatments
Treatment focuses on two goals: controlling current infections and strengthening the immune pathway that’s weakened by IL12B deficiency. Interferon‑gamma can help the body make up for the missing signal and is often used alongside targeted antibiotics. Starting antibiotics quickly when early symptoms of Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency appear can prevent complications. Not everyone responds to the same medication in the same way.
Recombinant interferon gamma‑1b is given by injection to boost the immune response against mycobacteria. It’s commonly used long term, with the dose and schedule tailored to age, weight, and infection history. Flu‑like symptoms and injection‑site irritation are the most common side effects.
Nontuberculous mycobacterial infections are treated with a macrolide (azithromycin or clarithromycin) plus rifampin or rifabutin and ethambutol. Severe disease may add an aminoglycoside such as amikacin. Courses are prolonged, often many months, and guided by susceptibility testing.
For confirmed TB, standard therapy typically includes isoniazid, rifampin, pyrazinamide, and ethambutol, with duration often extended in this condition. Drug choices may be adjusted for resistance patterns and drug interactions. Close monitoring for liver toxicity and vision changes is important.
Invasive Salmonella infections are treated with antibiotics such as ceftriaxone or ciprofloxacin. Longer courses are often needed to prevent relapse. Therapy is adjusted based on culture results and local resistance patterns.
Genetic influences
In Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency, the genetic driver is a change in both copies of the IL12B gene. This disrupts a key immune signal that normally helps the body switch on defenses against mycobacteria and related germs. Inheritance is recessive: when both parents carry one changed copy, each pregnancy has a 25% chance of a child being affected and a 50% chance of a child being a carrier. A “carrier” means you hold the gene change but may not show symptoms. Genetic testing for Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency can confirm the gene change and identify relatives who carry it, which can help with care planning and future pregnancies. Severity and age at first infection can vary even within the same family, because other genes and exposures also play a role.
Is Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency genetic?
Genetics are central in Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency. It’s caused by inherited changes in the IL12B gene, usually autosomal recessive, leading to absent IL-12/IL-23 signaling. Family testing and genetic counseling are important.
Pharmacogenetics—how genetics influence drug effects
Treatment choices are shaped by the specific IL12B change, because the defect blunts the normal IL‑12/IL‑23 signal that helps the body fight mycobacteria. Many with this condition receive prolonged combination antibiotics, and some benefit from interferon‑gamma injections that activate the same downstream defenses IL‑12 would normally trigger. Pharmacogenetic factors can also influence dosing and side‑effect risk with key drugs: with isoniazid, differences in the NAT2 enzyme may slow drug clearance, raising the chance of tingling in the hands and liver irritation, so doctors sometimes adjust the dose and use vitamin B6. If aminoglycosides such as amikacin or streptomycin are considered, a mitochondrial variant called MT‑RNR1 can greatly increase the risk of sudden hearing loss; testing can help avoid this complication. When trimethoprim–sulfamethoxazole is used for treatment or prevention, unrecognized G6PD deficiency can trigger breakdown of red blood cells, so screening is often considered in those from higher‑risk backgrounds. Genetic testing can sometimes identify how your body handles these medicines, helping tailor therapy for Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency.
Interactions with other conditions
Day to day, an exposure to tuberculosis germs or even foodborne Salmonella that might cause a mild illness in others can lead to a more serious, lingering infection. In Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency, the part of the immune response that helps the body fight mycobacteria is weakened, so infections like tuberculosis, the BCG vaccine strain, and nontyphoidal Salmonella tend to be more frequent and harder to clear. This creates important interactions with other diseases and exposures: the BCG vaccine (given at birth in many countries) can cause widespread infection, and close contact with someone who has active TB carries higher risk. HIV infection, severe malnutrition, or long-term use of steroids or TNF blockers for conditions like arthritis can further blunt immunity; a condition may “exacerbate” (make worse) symptoms of another. Gastrointestinal infections such as Salmonella may occur alongside mycobacterial illness, and coinfections in Mendelian susceptibility to mycobacterial diseases due to complete il12b deficiency can complicate diagnosis because fevers, weight loss, and swollen lymph nodes overlap. Live bacterial vaccines should generally be avoided, and doctors often coordinate care with infectious disease and immunology teams to plan prevention, screen close contacts, and choose antibiotics that won’t clash with treatments for any other ongoing conditions.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described stubborn, lingering infections that seemed unusually severe in otherwise healthy children. Families and communities once noticed patterns: a child who battled serious illness after a routine tuberculosis exposure, or repeated infections from “weak” environmental mycobacteria that others fought off with ease. From early theories to modern research, the story of Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency has followed this thread—why a few became very sick from germs that rarely cause trouble.
Early medical reports in the mid to late 20th century focused on unexplained, severe illness after BCG vaccination or after contact with tuberculosis. Doctors saw swollen lymph nodes, fevers that dragged on, and infections that returned after treatment. At that time, these patterns were grouped under broad labels like “atypical mycobacterial infections,” without a clear reason why they happened in certain families.
As immunology advanced, researchers uncovered a key pathway that helps immune cells talk to each other when they first encounter mycobacteria. They learned that a signaling protein called interleukin-12 (IL-12) acts like a relay, prompting other immune cells to release interferon-gamma, which then activates the body’s microbe-fighting machinery. In the 1990s, teams studying children with severe, selective vulnerability to mycobacteria traced the problem to changes in the IL12B gene, which provides instructions for a subunit of IL-12. Initially understood only through symptoms, later the condition gained a precise genetic explanation that fit the clinical picture.
Once considered rare, now recognized as part of a group called “Mendelian susceptibility to mycobacterial disease” (MSMD), complete IL12B deficiency showed that a single missing link in the IL-12/interferon-gamma pathway can leave people particularly open to mycobacterial infections while otherwise appearing healthy. Over time, descriptions became more detailed: some children had serious infections after BCG at birth; others reacted to common environmental mycobacteria; a few had added risks for certain salmonella infections, helping define the broader immune role of IL-12.
With each decade, genetic testing made diagnosis more straightforward, allowing clinicians to distinguish complete IL12B deficiency from similar conditions affecting the same pathway. This clarified family patterns, enabled counseling about inheritance, and guided treatment choices that support the interferon-gamma response.
Today, the history of Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency shows how careful bedside observations led to lab discoveries that changed care. Knowing the condition’s history helps explain why doctors ask about reactions to BCG, household tuberculosis exposures, and repeated infections that don’t match the usual pattern. It also highlights how a focused genetic cause can teach us about the immune system’s broader design, turning scattered case reports into a clear, actionable diagnosis.